Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Net Asset Value(s)

4 Apr 2023 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2023

Net asset values (“NAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2023.

B Shares

As at 31 March 2023, the unaudited NAV per B share was 73.8p and it is intended that this is the NAV per B share which will be used for the planned allotment of B shares on 5 April 2023.

This is a decrease of 8.8p from the latest published unaudited NAV of 82.6p as at 30 September 2022, predominantly as a result of a reduction in the share prices of some of the B share pool’s AIM quoted investments.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2023 was 85.8p.

The unaudited NAV per B share as at 31 December 2022 was 80.7p, full details of which will be included in our Final Results announcement later this month.

The B share Offer by the Company remains open for the 2022/23 tax year until midday today, 4 April 2023.

The B share Offer remains open for the 2023/24 tax year until 18 August 2023, unless the Offer has been fully subscribed by an earlier date or is closed earlier at the discretion of the Directors.

Ordinary Shares

As at 31 March 2023, the unaudited NAV per Ordinary share was 28.4p.

This is a decrease of 11.6p from the latest published unaudited NAV as at 5 December 2022 of 40.0p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc offset by an increase in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2023, shares in Scancell Holdings Plc were valued at 15.5p per share (5 December 2022: 23p) and shares in Arecor Therapeutics Plc were valued at 250p per share (5 December 2022: 240p).

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2023 was 99.7p.

The unaudited NAV per Ordinary share as at 31 December 2022 was 37.1p, full details of which will be included in our Final Results announcement later this month.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
18th May 20231:38 pmGNWDirectorate Changes
18th May 20231:32 pmGNWResults of Annual General Meeting Voting
3rd May 20234:01 pmGNWIssue of Equity and Total Voting Rights
27th Apr 202311:25 amGNWPublication of a Supplementary Prospectus
21st Apr 20237:00 amGNWFinal Results for the Year Ended 31 December 2022
5th Apr 20233:05 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20237:00 amGNWNet Asset Value(s)
7th Mar 20231:30 pmGNWInterim Dividend Declarations
21st Dec 20227:00 amGNWB Share Portfolio Update
7th Dec 20227:00 amGNWOrdinary Share NAV Update and Dividend Declaration
30th Nov 202212:33 pmGNWDirector/PDMR Shareholding
30th Nov 202212:29 pmGNWIssue of Equity and Total Voting Rights
19th Oct 20227:00 amGNWSecond Interim Dividend on B Shares
13th Oct 20227:00 amGNWNAV Update
26th Aug 202211:56 amGNWOffer for Subscription and Publication of Prospectus
22nd Aug 20222:53 pmGNWPDMR Shareholding
22nd Aug 20222:46 pmGNWIssue of Equity and Total Voting Rights
16th Aug 20227:00 amGNWB Share Closure of Offer for Subscription
15th Jul 20227:00 amGNWHalf-year report
30th Jun 202210:17 amGNWIssue of Supplementary Prospectus
23rd May 20227:00 amGNWShare Buy-back and TVR
23rd May 20227:00 amGNWAppointment of Auditor
4th May 202211:25 amGNWIssue of Equity and Total Voting Rights
27th Apr 20223:42 pmGNWResult of AGM
5th Apr 20221:56 pmGNWIssue of Equity and Total Voting Rights
1st Apr 20221:43 pmGNWIssue of Equity and Total Voting Rights
1st Apr 202211:05 amGNWNAV Update
25th Mar 202210:00 amGNWIssue of Supplementary Prospectus
25th Mar 20227:01 amGNWNAV Update
25th Mar 20227:00 amGNWFinal Results for the Year Ended 31 December 2021
8th Mar 20227:00 amGNWInterim Dividend on B Shares
10th Dec 202111:40 amGNWDirector/PDMR Shareholding
8th Dec 20213:24 pmGNWIssue of Equity and Total Voting Rights
16th Nov 20217:00 amGNWSecond Interim Dividend on B Shares
29th Oct 202111:42 amGNWOffer for Subscription and Publication of Prospectus
28th Oct 20211:06 pmGNWTR-1: Notification of major holdings
21st Oct 20219:01 amGNWNAV Update
16th Sep 202112:16 pmRNSSecond Price Monitoring Extn
16th Sep 202112:14 pmRNSPrice Monitoring Extension
14th Sep 20212:07 pmRNSSecond Price Monitoring Extn
14th Sep 20212:01 pmRNSPrice Monitoring Extension
25th Aug 20214:41 pmRNSSecond Price Monitoring Extn
25th Aug 20214:36 pmRNSPrice Monitoring Extension
12th Aug 20214:42 pmRNSSecond Price Monitoring Extn
12th Aug 20214:38 pmRNSPrice Monitoring Extension
26th Jul 20217:00 amGNWHalf-year report
15th Jun 202112:18 pmGNWIssue of Equity and Total Voting Rights
15th Jun 20217:00 amGNWB Share Net Asset Value
3rd Jun 202110:51 amGNWInterim Capital Dividend on Ordinary Shares
20th May 20217:00 amGNWB Share Extension of Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.